abstract |
The present invention relates to solid dosage forms comprising ERβ-selective ligands comprising benzoxazole, and to methods of preparing such formulations, and more particularly to novel formulations comprising ERβ-selective ligands, ERB-041 and the formulations thereof. It relates to a manufacturing method. |